Alexi A Wright1, Angel Cronin2, Dana E Milne2, Michael A Bookman2, Robert A Burger2, David E Cohn2, Mihaela C Cristea2, Jennifer J Griggs2, Nancy L Keating2, Charles F Levenback2, Gina Mantia-Smaldone2, Ursula A Matulonis2, Larissa A Meyer2, Joyce C Niland2, Jane C Weeks2, David M O'Malley2. 1. Alexi A. Wright, Angel Cronin, Dana E. Milne, Nancy L. Keating, Ursula A. Matulonis, and Jane C. Weeks, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Michael A. Bookman, University of Arizona Cancer Center, Tucson, AZ; Robert A. Burger, University of Pennsylvania; Gina Mantia-Smaldone, Fox Chase Cancer Center, Philadelphia, PA; David E. Cohn and David M. O'Malley, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mihaela Cristea and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte, CA; Jennifer J. Griggs, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Charles F. Levenback and Larissa A. Meyer, The University of Texas MD Anderson Cancer Center, Houston, TX. alexi_wright@dfci.harvard.edu. 2. Alexi A. Wright, Angel Cronin, Dana E. Milne, Nancy L. Keating, Ursula A. Matulonis, and Jane C. Weeks, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Michael A. Bookman, University of Arizona Cancer Center, Tucson, AZ; Robert A. Burger, University of Pennsylvania; Gina Mantia-Smaldone, Fox Chase Cancer Center, Philadelphia, PA; David E. Cohn and David M. O'Malley, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mihaela Cristea and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte, CA; Jennifer J. Griggs, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Charles F. Levenback and Larissa A. Meyer, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
PURPOSE: A 2006 randomized trial demonstrated a 16-month survival benefit with intraperitoneal and intravenous (IP/IV) chemotherapy administered to patients who had ovarian cancer, compared with IV chemotherapy alone, but more treatment-related toxicities. The objective of this study was to examine the use and effectiveness of IP/IV chemotherapy in clinical practice. PATIENTS AND METHODS: Prospective cohort study of 823 women with stage III, optimally cytoreduced ovarian cancer diagnosed at six National Comprehensive Cancer Network institutions. We examined IP/IV chemotherapy use in all patients diagnosed between 2003 and 2012 (N = 823), and overall survival and treatment-related toxicities with Cox regression and logistic regression, respectively, in a propensity score-matched sample (n = 402) of patients diagnosed from 2006 to 2012, excluding trial participants, to minimize selection bias. RESULTS: Use of IP/IV chemotherapy increased from 0% to 33% between 2003 and 2006, increased to 50% from 2007 to 2008, and plateaued thereafter. Between 2006 and 2012, adoption of IP/IV chemotherapy varied by institution from 4% to 67% (P < .001) and 43% of patients received modified IP/IV regimens at treatment initiation. In the propensity score-matched sample, IP/IV chemotherapy was associated with significantly improved overall survival (3-year overall survival, 81% v 71%; hazard ratio, 0.68; 95% CI, 0.47 to 0.99), compared with IV chemotherapy, but also more frequent alterations in chemotherapy delivery route (adjusted rates discontinuation or change, 20.4% v 10.0%; adjusted odds ratio, 2.83; 95% CI, 1.47 to 5.47). CONCLUSION: Although the use of IP/IV chemotherapy increased significantly at National Comprehensive Cancer Network centers between 2003 and 2012, fewer than 50% of eligible patients received it. Increasing IP/IV chemotherapy use in clinical practice may be an important and underused strategy to improve ovarian cancer outcomes.
PURPOSE: A 2006 randomized trial demonstrated a 16-month survival benefit with intraperitoneal and intravenous (IP/IV) chemotherapy administered to patients who had ovarian cancer, compared with IV chemotherapy alone, but more treatment-related toxicities. The objective of this study was to examine the use and effectiveness of IP/IV chemotherapy in clinical practice. PATIENTS AND METHODS: Prospective cohort study of 823 women with stage III, optimally cytoreduced ovarian cancer diagnosed at six National Comprehensive Cancer Network institutions. We examined IP/IV chemotherapy use in all patients diagnosed between 2003 and 2012 (N = 823), and overall survival and treatment-related toxicities with Cox regression and logistic regression, respectively, in a propensity score-matched sample (n = 402) of patients diagnosed from 2006 to 2012, excluding trial participants, to minimize selection bias. RESULTS: Use of IP/IV chemotherapy increased from 0% to 33% between 2003 and 2006, increased to 50% from 2007 to 2008, and plateaued thereafter. Between 2006 and 2012, adoption of IP/IV chemotherapy varied by institution from 4% to 67% (P < .001) and 43% of patients received modified IP/IV regimens at treatment initiation. In the propensity score-matched sample, IP/IV chemotherapy was associated with significantly improved overall survival (3-year overall survival, 81% v 71%; hazard ratio, 0.68; 95% CI, 0.47 to 0.99), compared with IV chemotherapy, but also more frequent alterations in chemotherapy delivery route (adjusted rates discontinuation or change, 20.4% v 10.0%; adjusted odds ratio, 2.83; 95% CI, 1.47 to 5.47). CONCLUSION: Although the use of IP/IV chemotherapy increased significantly at National Comprehensive Cancer Network centers between 2003 and 2012, fewer than 50% of eligible patients received it. Increasing IP/IV chemotherapy use in clinical practice may be an important and underused strategy to improve ovarian cancer outcomes.
Authors: Jason A Konner; Diana M Grabon; Scott R Gerst; Alexia Iasonos; Howard Thaler; Sandra D Pezzulli; Paul J Sabbatini; Katherine M Bell-McGuinn; William P Tew; Martee L Hensley; David R Spriggs; Carol A Aghajanian Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Kathleen M Fairfield; Kimberly Murray; Jason A LaChance; Heidi R Wierman; Craig C Earle; Edward L Trimble; Joan L Warren Journal: Gynecol Oncol Date: 2014-06-18 Impact factor: 5.482
Authors: Joyce N Barlin; Fanny Dao; Nadim Bou Zgheib; Sarah E Ferguson; Paul J Sabbatini; Martee L Hensley; Katherine M Bell-McGuinn; Jason Konner; William P Tew; Carol Aghajanian; Dennis S Chi Journal: Gynecol Oncol Date: 2012-03-21 Impact factor: 5.482
Authors: Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter Journal: N Engl J Med Date: 1996-12-26 Impact factor: 91.245
Authors: Laurie Elit; Thomas K Oliver; Allan Covens; Janice Kwon; Michael Fung-Kee Fung; Holger W Hirte; Amit M Oza Journal: Cancer Date: 2007-02-15 Impact factor: 6.860
Authors: Lisa M Landrum; James Java; Cara A Mathews; Grainger S Lanneau; Larry J Copeland; Deborah K Armstrong; Joan L Walker Journal: Gynecol Oncol Date: 2013-04-08 Impact factor: 5.482
Authors: Renee A Cowan; Roisin E O'Cearbhaill; Ginger J Gardner; Douglas A Levine; Kara Long Roche; Yukio Sonoda; Oliver Zivanovic; William P Tew; Evis Sala; Yulia Lakhman; Hebert A Vargas Alvarez; Debra M Sarasohn; Svetlana Mironov; Nadeem R Abu-Rustum; Dennis S Chi Journal: Ann Surg Oncol Date: 2015-10-28 Impact factor: 5.344
Authors: Derek Hargrove; Brian Liang; Raana Kashfi-Sadabad; Gaurav N Joshi; Laura Gonzalez-Fajardo; Sterling Glass; Michael Jay; Andrew Salner; Xiuling Lu Journal: J Control Release Date: 2020-11-07 Impact factor: 9.776
Authors: Danielle A Jandial; William E Brady; Stephen B Howell; Heather A Lankes; Russell J Schilder; Jan H Beumer; Susan M Christner; Sandra Strychor; Matthew A Powell; Andrea R Hagemann; Kathleen N Moore; Joan L Walker; Paul A DiSilvestro; Linda R Duska; Paula M Fracasso; Don S Dizon Journal: Gynecol Oncol Date: 2017-03-22 Impact factor: 5.482
Authors: Larissa A Meyer; Angel M Cronin; Charlotte C Sun; Kristin Bixel; Michael A Bookman; Mihaela C Cristea; Jennifer J Griggs; Charles F Levenback; Robert A Burger; Gina Mantia-Smaldone; Ursula A Matulonis; Joyce C Niland; David M O'Malley; Alexi A Wright Journal: J Clin Oncol Date: 2016-11-10 Impact factor: 44.544
Authors: Natalie Boehnke; Santiago Correa; Liangliang Hao; Wade Wang; Joelle P Straehla; Sangeeta N Bhatia; Paula T Hammond Journal: Angew Chem Int Ed Engl Date: 2020-01-07 Impact factor: 15.336
Authors: L Wenzel; D Mukamel; K Osann; L Havrilesky; L Sparks; J Lipscomb; A A Wright; J Walker; R Alvarez; L Van Le; K Robison; R Bristow; R Morgan; B J Rimel; H Ladd; S Hsieh; A Wahi; D Cohn Journal: Contemp Clin Trials Date: 2017-03-19 Impact factor: 2.226
Authors: Aaron H Colby; Nicholas H Oberlies; Cedric J Pearce; Victoria L M Herrera; Yolonda L Colson; Mark W Grinstaff Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2017-02-09
Authors: Brooke A Schlappe; Jennifer J Mueller; Oliver Zivanovic; Ginger J Gardner; Kara Long Roche; Yukio Sonoda; Dennis S Chi; Roisin E O'Cearbhaill Journal: Gynecol Oncol Date: 2016-05-21 Impact factor: 5.482